Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report.
J Thorac Oncol
; 19(9): 1352-1355, 2024 Sep.
Article
em En
| MEDLINE
| ID: mdl-38912994
ABSTRACT
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the standard of care for patients with advanced NSCLC and EGFR-sensitizing mutations. Both in osimertinib pivotal trials and in the post-marketing phase, asymptomatic creatinine phosphokinase elevation and clinically relevant muscle damage have been reported. However, the mechanisms underlying these conditions remain unclear. Herein, we report the first muscle biopsy description of osimertinib-induced myopathy and hypothesize that the mechanisms underpinning muscle toxicity could be driven by hyporegenerative mechanisms and mitochondrial dysfunction with subsequent reduced metabolic endurance, both directly linked to the inhibition of downstream molecular pathways mediated by EGFR in muscle cells.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Acrilamidas
/
Compostos de Anilina
/
Doenças Musculares
Limite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Thorac Oncol
/
J. thorac. oncol
/
Journal of thoracic oncology
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Itália